GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » Earnings per Share (Diluted)

Procaps Group (Procaps Group) Earnings per Share (Diluted) : $0.52 (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Procaps Group Earnings per Share (Diluted)?

Procaps Group's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $0.08. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.52.

Procaps Group's EPS (Basic) for the three months ended in Sep. 2023 was $0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.52.

Procaps Group's EPS without NRI for the three months ended in Sep. 2023 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $0.03.

During the past 12 months, Procaps Group's average EPS without NRIGrowth Rate was -92.10% per year.


Procaps Group Earnings per Share (Diluted) Historical Data

The historical data trend for Procaps Group's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group Earnings per Share (Diluted) Chart

Procaps Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Earnings per Share (Diluted)
-0.17 -0.11 -1.03 0.42

Procaps Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.10 0.07 0.27 0.08

Competitive Comparison of Procaps Group's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procaps Group's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where Procaps Group's PE Ratio falls into.



Procaps Group Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Procaps Group's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(42.54-0)/101.110
=0.42

Procaps Group's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2023 is calculated as

Diluted Earnings Per Share (Q: Sep. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(8.194-0)/102.425
=0.08

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Procaps Group  (NAS:PROC) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Procaps Group Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Procaps Group's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Procaps Group (Procaps Group) Business Description

Traded in Other Exchanges
Address
9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Executives
Alexandre Weinstein Manieu director, 10 percent owner CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski director, 10 percent owner, officer: Chief Executive Officer 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski director, 10 percent owner 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust 10 percent owner OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a. 10 percent owner 3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371